← Back to Search

Behavioural Intervention

Educational Program for Alzheimer's Disease (DPRESCRIBE-AD2 Trial)

N/A
Waitlist Available
Led By Jerry H Gurwitz, MD
Research Sponsored by University of Massachusetts, Worcester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to study how educating patients, caregivers, and healthcare providers about inappropriate prescribing of medications can help reduce medication-related issues in older adults with Alzheimer's disease. The study will use a health plan

Who is the study for?
This trial is for older adults with Alzheimer's Disease who live in the community, have been diagnosed based on specific codes or are taking Alzheimer's medication, and may be receiving potentially inappropriate medications like sedatives or antipsychotics.
What is being tested?
The study tests an educational program designed to inform patients with Alzheimer's and their caregivers about the risks of certain medications. The goal is to see if this education can reduce unnecessary or harmful prescriptions compared to usual care.
What are the potential side effects?
Since the intervention involves educational materials rather than drugs, there are no direct side effects from medication. However, changes in prescription practices as a result of the education could lead to withdrawal symptoms or other effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Absence of Inappropriate Medication Prescription Dispensing
Secondary study objectives
Dose Change
Mortality
Polypharmacy
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Two MailingsExperimental Treatment1 Intervention
A combined patient/caregiver and provider educational intervention with a second identical mailing, following the first within 45 days
Group II: Single MailingExperimental Treatment1 Intervention
A combined patient/caregiver and provider educational intervention with one mailing to each.
Group III: Usual CareActive Control1 Intervention

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH
1,782 Previous Clinical Trials
28,172,718 Total Patients Enrolled
Carelon ResearchOTHER
75 Previous Clinical Trials
208,630 Total Patients Enrolled
Harvard Pilgrim Health CareOTHER
59 Previous Clinical Trials
24,974,698 Total Patients Enrolled
~6205 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top